Search research articles
Contact Us
Filters
Showing results (11-20 of 104) with videos related to
Page
of 11
Sort By:
Expert Review of Cardiovascular Therapy
|
August 4, 2005
Ximelagatran for stroke prevention in atrial fibrillation
Christopher J Boos, Gregory Y H Lip
Journal of the American College of Cardiology
|
February 21, 2006
Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Christopher J Boos, Gregory Y H Lip
American Journal of Hypertension
|
May 2, 2006
Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction?
Christopher J Boos, Gregory Y H Lip
Expert Opinion on Investigational Drugs
|
November 30, 2004
Novel therapies for the prevention of stroke
Christopher J Boos, Gregory Y H Lip
Arteriosclerosis, Thrombosis, and Vascular Biology
|
January 21, 2006
Assessment of hemostatic risk factors in predicting arterial thrombotic events
Christopher J Boos, Gregory Y H Lip
The American Journal of Cardiology
|
September 26, 2006
C-reactive protein and lone atrial fibrillation: potential confounders
Christopher J Boos, Gregory Y H Lip
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 1, 2005
Ethnic differences in arterial responses, inflammation, and metabolic profiles: possible insights into ethnic differences in cardiovascular disease and stroke
Gregory Y H Lip, Christopher J Boos
Journal of Clinical Hypertension (Greenwich, Conn.)
|
January 18, 2024
Ambulatory arterial stiffness index, mortality, and adverse cardiovascular outcomes; Systematic review and meta-analysis
Christopher J Boos, Aung Hein, Ahmed Khattab
Thrombosis Research
|
April 22, 2006
Ximelagatran: an eulogy
Christopher J Boos, Gregory Y H Lip
Journal of Thrombosis and Thrombolysis
|
November 2, 2005
Biomarkers in atrial fibrillation: further observations on biologic plausibility, cause and effect
Christopher J Boos, Gregory Y H Lip
Page
of 11
Search research articles
Search
Showing results (11-20 of 104) with videos related to
Sort By:
Page
of 11
Expert Review of Cardiovascular Therapy
|
August 4, 2005
Ximelagatran for stroke prevention in atrial fibrillation
Christopher J Boos, Gregory Y H Lip
Journal of the American College of Cardiology
|
February 21, 2006
Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Christopher J Boos, Gregory Y H Lip
American Journal of Hypertension
|
May 2, 2006
Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction?
Christopher J Boos, Gregory Y H Lip
Expert Opinion on Investigational Drugs
|
November 30, 2004
Novel therapies for the prevention of stroke
Christopher J Boos, Gregory Y H Lip
Arteriosclerosis, Thrombosis, and Vascular Biology
|
January 21, 2006
Assessment of hemostatic risk factors in predicting arterial thrombotic events
Christopher J Boos, Gregory Y H Lip
The American Journal of Cardiology
|
September 26, 2006
C-reactive protein and lone atrial fibrillation: potential confounders
Christopher J Boos, Gregory Y H Lip
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 1, 2005
Ethnic differences in arterial responses, inflammation, and metabolic profiles: possible insights into ethnic differences in cardiovascular disease and stroke
Gregory Y H Lip, Christopher J Boos
Journal of Clinical Hypertension (Greenwich, Conn.)
|
January 18, 2024
Ambulatory arterial stiffness index, mortality, and adverse cardiovascular outcomes; Systematic review and meta-analysis
Christopher J Boos, Aung Hein, Ahmed Khattab
Thrombosis Research
|
April 22, 2006
Ximelagatran: an eulogy
Christopher J Boos, Gregory Y H Lip
Journal of Thrombosis and Thrombolysis
|
November 2, 2005
Biomarkers in atrial fibrillation: further observations on biologic plausibility, cause and effect
Christopher J Boos, Gregory Y H Lip
Page
of 11